Search

everythinglearnresearchcommunity

for

Search:↓

The user has been on finasteride for 1.5 years with good results but avoids minoxidil due to pet safety concerns. They're considering alternatives like Redensyl and natural remedies like rosemary oil and stinging nettle tincture for hair loss.

Rosemary oil is compared to minoxidil 2%, but its effectiveness and safety are questioned. Minoxidil 5% is considered safer and more reliable for hair loss prevention.

RU58841 is discussed as a topical anti-androgen for hair loss, but its effectiveness and safety are not well-documented, leading to mixed opinions and experiences among users. Some combine it with finasteride, but concerns about side effects and lack of FDA approval limit its popularity.

The conversation discusses combining topical cetirizine with minoxidil for hair loss treatment and inquires about the safety and absorption through the skin, as well as the possibility of adding melatonin.

The conversation discusses Kintor's initiation of a new Phase 3 trial to assess the long-term safety of Pyrilutamide (KX-826) for hair loss, which will last 52 weeks. Specific treatments mentioned include Pyrilutamide.

Taking topical minoxidil orally for hair loss treatment, discussing safety, dosing, side effects, and FAQs. Users express concerns about safety and potential heart damage, while others share experiences and results.

Hair loss treatments Finasteride and Dutasteride are discussed, with emphasis on their safety and effectiveness. Users share frustration about fear-mongering and side effect discussions, suggesting trust in scientific studies and FDA approval.

Treatments for hair loss, such as topical minoxidil, platelet-rich plasma therapy with or without minoxidil, ketoconazole, non-abative radio frequency, natural products, finasteride and cortexolone 17 alpha propionate. The post evaluates the efficacy and safety of these treatments in various studies.

Using Vitamin C serum after dermarolling may help with healing and hair health. The safety of additional ingredients like Glycerin, Propylene Glycol, Phenoxyethanol, Sodium Benzoate, and Sodium Metabisulfite in hair regrowth is questioned.

A user started taking oral minoxidil using Rogaine, despite concerns from others about its safety and proper use. They plan to update on their progress.

The conversation discusses using topical finasteride for hair loss, with concerns about its safety around family members, especially pregnant women and infants. One user plans to try topical finasteride due to side effects from the pill.

The user experienced increased hair thinning after switching from finasteride and minoxidil to dutasteride, despite some users suggesting it might be a temporary shedding phase. The user is considering using RU58841 but is unsure about its safety.

A user plans to stop Dutasteride to conceive a child, seeking advice on hair maintenance. Suggestions include switching to Finasteride, but many emphasize prioritizing child safety.

Topical finasteride is less popular due to inconvenience, cost, and availability, while oral finasteride is favored for ease and safety. Some users experience side effects with topical use, but find it effective with minoxidil, though opinions on its efficacy vary.

The DNA Trichotest is considered unreliable for predicting hair loss treatment responses, and topical spironolactone is questioned for its effectiveness and safety in cis males. Finasteride and Dutasteride are recommended as more reliable treatments for androgenic alopecia.

Cyperus rotundus oil is suggested as a natural treatment for androgenic alopecia, potentially inhibiting hair growth without affecting testosterone levels. The conversation questions its effectiveness and safety for scalp use.

RU58841 users report mixed results, with some experiencing no benefits and others noting regrowth but potential side effects. Many prefer finasteride and minoxidil due to better-studied safety profiles.

The conversation discusses androgen receptor degraders for hair loss, highlighting their potential advantages over traditional AR blockers like RU58841 and pyrilutamide. Concerns about the safety and cost of these treatments are also mentioned.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.

FOL-005 claims to be more effective than Minoxidil and Finasteride but lacks anti-DHT properties, leading to potential reduced efficacy over time. Concerns are raised about misleading marketing and the safety of alternative treatments like Pyrilutamide and Clascoterone.

PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.

A user is considering buying RU58841 powder from Aliexpress to mix with Minoxidil for hair loss treatment. Another user warns about the safety concerns of RU58841, especially from unreliable sources, and suggests trying finasteride, oral Minoxidil, and dutasteride first.

A user is considering using 70% isopropyl alcohol with glycerin as a carrier for topical finasteride for hair loss but is concerned about its safety compared to ethanol. They are unsure where to buy ethanol without toxic methanol.

The user is considering using 2.5mg of oral minoxidil daily and 5% topical minoxidil every other day on their hairline, in addition to their current regimen of 1mg finasteride and RU58841. They are seeking advice on the safety and effectiveness of this combination.

A user received a prescription for a topical solution with Minoxidil 7%, Finasteride 2%, and Tretinoin 0.01%, to be used twice daily for three months. They are concerned about the safety of these dosages compared to commonly recommended lower dosages.

The conversation is about the effectiveness of finasteride, oral minoxidil, and RU58841 for hair loss treatment. Opinions vary on improvement after 7 months of treatment, and there are concerns about the safety of using non-approved chemicals like RU58841.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

A user on finasteride for hair loss is considering topical dutasteride to further reduce scalp DHT and is using various other topicals as substitutes for minoxidil due to concerns about the safety of their cats and potential heart side effects from oral minoxidil. They are exploring whether a once-weekly application of topical dutasteride would be effective.